Cancer Genome Chaos Decoded: A New Lexicon for Complex Mutation Patterns
A landmark review maps the full landscape of complex mutational phenomena in cancer genomes, clarifying mechanisms tied to tumor evolution and drug resistance.
Summary
Most mutations in cancer are scattered randomly, but some arrive in organized bursts. Over 15 years, researchers have named these patterns with Greek terms: kataegis (thunderstorm), omikli (fog), kyklonas (cyclone), chromothripsis (chromosome shattering), chromoplexy, pyrgo (tower), rigma (chasm) and tyfonas (typhoon). This Perspective gathers them into one lexicon. It clarifies how each is defined, how it forms, and what it does to a tumor. Many of these patterns are tied to enzymes called APOBEC, to errors in DNA repair and replication, and to circular DNA that drives oncogene amplification. Several are linked to drug resistance and poor survival. The authors argue that clinical use lags because whole-genome sequencing is not yet routine, and they point to early therapeutic ideas such as APOBEC3 inhibitors.
Detailed Summary
Cancer genomes are mostly shaped by randomly scattered mutations, but a subset arrives in organized, clustered bursts that reveal how DNA damage and repair go wrong. Over 15 years, whole-genome sequencing has uncovered many such events, often given Greek names. Because definitions overlap and mechanisms remain debated, this Nature Cancer Perspective from Alexandrov's group at UC San Diego and Imieliński's group at NYU Langone assembles a single lexicon of 13 complex mutational phenomena, summarized in a master table.
The first group is clustered base substitutions. Kataegis is defined as four or more mutations with intermutational distances under 10 kb, typically from APOBEC or AID deaminases acting on long single-stranded DNA exposed during double-strand break repair. About 36% of kataegis sits within 10 kb of a structural variant breakpoint. Omikli is a diffuse pattern of two to three mutations, with median cluster sizes of about 2.2 versus 4.37 for kataegis. Omikli is tied to mismatch repair and replication-fork exposure. Kyklonas is kataegis on circular extrachromosomal DNA (ecDNA). About 33% of ecDNAs carry at least one such event, roughly 98% of them APOBEC signatures SBS2 and SBS13.
The second group is structural. Chromothripsis, the shattering and random religation of chromosomes, usually begins when a micronucleus ruptures. It appears in an estimated 40–60% of cancers and is linked to poor prognosis. Chromoplexy involves fewer than ten breakpoints, each on a different chromosome, and occurs in roughly 10% of cases. It was first found in prostate cancer, where it generates TMPRSS2–ERG fusions. Chromoanasynthesis arises from replication fork stalling and template switching rather than shattering. Loss–translocation–amplification and translocation–bridge amplification couple tumor suppressor loss with oncogene amplification in osteosarcoma and breast cancer.
The third group is complex copy-number patterns. Pyrgo ('tower') comes from nested tandem duplications formed by microhomology-mediated break-induced replication, and it concentrates at early-replicating super-enhancers. Rigma ('chasms') are stepwise deletions at late-replicating fragile sites such as FHIT. Tyfonas are tens-of-megabase amplifications at tens to hundreds of copies, proposed to result from slow, multi-cell-cycle reassembly of a shattered chromosome. They are rare overall (under 5% of samples) but common in primary breast cancer, acral melanoma and dedifferentiated liposarcoma.
Clinically, kataegis is linked to poor outcome in multiple myeloma and to therapy resistance in lung and breast cancer. Tumors with ecDNA tend to resist drugs and have worse outcomes. Chromothripsis amplifies MAPK inhibitor resistance genes in metastatic melanoma. Therapeutic ideas include APOBEC3 inhibitors and HMCES loss, which is synthetically lethal in APOBEC3A-expressing, TP53-mutant cells. Hydroxyurea and BET inhibitors have been proposed against ecDNA. The authors also note that CRISPR–Cas9 editing can cause large rearrangements, and that clustered mutations occur in aging oocytes and may be relevant to somatic mosaicism in normal aging tissue.
This is a conceptual Perspective, not a new dataset, and many proposed mechanisms, especially for tyfonas, kyklonas and chromoplexy, remain unvalidated. The clinical relevance of most phenomena beyond kataegis is largely unexplored. Translation is held back by the lack of routine whole-genome sequencing in the clinic.
Key Findings
- Thirteen complex mutational phenomena are cataloged, including kataegis, omikli, kyklonas, chromothripsis, chromoplexy, pyrgo, rigma and tyfonas.
- Kataegis requires 4+ clustered mutations within 10 kb; omikli has 2–3 mutations, with median cluster sizes of about 4.37 vs 2.2 mutations.
- About 36% of kataegis lies within 10 kb of a structural variant breakpoint, supporting a link to double-strand break repair.
- About 33% of ecDNAs harbor at least one kyklonic event, and roughly 98% of these reflect APOBEC signatures SBS2 and SBS13.
- Chromothripsis occurs in an estimated 40–60% of cancers and is associated with poor prognosis. Chromoplexy occurs in about 10% of cases.
- Tyfonas are rare (<5% of samples) but frequent in primary breast cancer, acral melanoma and dedifferentiated liposarcoma.
- HMCES loss is synthetically lethal with APOBEC3A activity, especially in TP53-mutant cells, which points to a possible therapeutic target.
Methodology
This is a narrative Perspective in Nature Cancer, not a systematic review or original study, so it reports no new sample sizes or statistical tests. The authors synthesize roughly 15 years of whole-genome sequencing, computational and experimental literature, with the main definitions summarized in a lexicon table and mechanism schematics. Quantitative figures come from cited pan-cancer analyses and from earlier work by the authors' group (for example, clustered mutation mapping across thousands of genomes).
Study Limitations
The authors note that mechanisms for several phenomena, especially tyfonas, kyklonas and chromoplexy, remain unvalidated or only inferred. The clinical impact of most events other than kataegis is largely understudied, and few targeted therapies exist. As a Perspective it reflects the authors' selection and interpretation of the literature, and no conflicts of interest were stated in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: